Wednesday, September 23Wednesday, 23 September 2026 - EST (Eastern Time, UTC-05:00

This interactive workshop will guide biotech management teams through a practical framework for approaching valuation in strategic partnering situations, from assessing core asset attributes to understanding how negotiation dynamics and deal terms shape perspectives value. Participants will explore how scientific differentiation, development stage, risk profile, and commercial potential translates into intrinsic value assumptions, and how partnering structures, market dynamics and other external factors may influence headline value and partner alignment.

The RNA Leaders CEO Forum is an exclusive group workshop that brings together CEO’s from the RNA therapeutics space to collaboratively discuss challenges, share insights, and brainstorm strategic solutions in a peer-to-peer setting. This year's forum will focus specifically on the strategic opportunity and challenges of moving to China for RNA drug development, covering critical topics including regulatory navigation, market access, manufacturing considerations, intellectual property protection, and partnership strategies. Participants will gain actionable insights from their peers' experiences and expand their network of trusted industry colleagues.

• Building a pharma innovation ecosystem for RNA therapeutics: implementing structured scouting frameworks, venture partnerships, and co-development agreements to complement internal R&D and rapidly advance promising RNA candidates to the clinic
• De-risking RNA programs through external expertise: accessing specialized manufacturing, analytical, and regulatory knowledge to navigate complex development challenges and achieve faster IND submissions and clinical proof-of-concept

• Decoding the RNA M&A landscape: key drivers behind recent mega-deals, valuation metrics for emerging modalities, and strategic rationale for Big Pharma partnerships versus full acquisitions

• Advances in how siRNA medicines are manufactured and delivered are reshaping the landscape of RNA therapeutics and their expansion into broader indications. As alternative production technologies mature, they offer new opportunities to improve scalability and support reliable supply for widespread use.

• With these advances comes an evolving set of responsibilities for the industry. Manufacturers are increasingly expected to pair scientific innovation with practical strategies that enable real-world deployment—through sustainable scalable manufacturing, rational pricing structures, and programs that help ensure therapies move from approval to routine use. In parallel, regulators play a critical role by establishing pathways that fast-track review processes and promote global regulatory alignment, reducing friction between development milestones and patient adoption.

• This session explores how progress in alternative production technologies like the Enzymatic Catalyzed Oligonucleotide (ECO) Synthesis® Manufacturing Platform can ensure the promise of siRNA therapeutics is fully realized.

• Leveraging computational intelligence to transform RNA therapeutics: from target identification and molecular design to personalized treatment strategies for rare disease populations

• Bridging the gap between AI innovation and clinical reality: case studies in RNA drug development, regulatory considerations, and translational pathways to patient care